Gallagher, Eileen

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,888

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 2,420

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,097

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchEvolution and Genetic Dynamics

Cited by 1,006

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 807

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 785

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 728

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., et al. (2021) · The Lancet Public Health

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 304

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

Kirsebom, F. C. M., Andrews, N., Stowe, J., Toffa, S., Sachdeva, R., Gallagher, E., Groves, N., O'Connell, A.-M., Chand, M., Ramsay, M., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 182